Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.42 |
| ▸ | ESR1 | P03372 | 7/20 | 0.42 |
| ▸ | AR | P10275 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30230881 | 1.00 | CYP1A2 (0.42) | CYP1A2CYP3A4TSHRMAPK1ADRB2 | |
| SCHEMBL1622233 | 0.82 | CA9 (0.46) | CYP1A2CYP3A4ESR2ESR1AR | |
| Hydroquinone SCHEMBL11481972 | 0.81 | NR4A1 (0.45) | CYP1A2CYP3A4TSHRMAPK1ADRB2 | |
| SCHEMBL1697195 | 0.78 | CA9 (0.46) | ESR2ESR1ARCA9CA12 | |
| SCHEMBL29473510 | 0.78 | CA9 (0.46) | ESR2ESR1ARCA9CA12 | |
| SCHEMBL29802150 | 0.76 | KDM4E (0.55) | CYP1A2CYP3A4TSHRMAPK1ADRB2 | |
| SCHEMBL5072719 | 0.76 | TDP1 (0.48) | CYP1A2CYP3A4TSHRMAPK1ADRB2 | |
| SCHEMBL615129 | 0.76 | KDM4E (0.55) | CYP1A2CYP3A4TSHRMAPK1ADRB2 | |
| SCHEMBL1267040 | 0.76 | ESR2 (0.44) | ESR2ESR1ARCA9CA12 | |
| SCHEMBL17498291 | 0.75 | KDM4E (0.39) | ESR2ESR1ARCA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023031308-A1 | CCR2 INHIBITORS | ARTICA THERAPEUTICS B.V. (NL) | 2023-03-09 | — | — | WO | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-4713383-A | ADENOSINE AND BENZODIAZEPINE ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1987-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | CYP1A2 4055/4885CYP3A4 3918/4885TSHR 2644/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | CYP1A2 4055/4885CYP3A4 3918/4885TSHR 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.